<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        192-186-03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AZOMYCIN 200MG\5ML SUSP.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        43.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine contains azithromycin, which is one of a group of antibiotics called macrolides. It is used to treat infections caused by certain bacteria and other micro-organisms, which include:</p><p>-&nbsp;&nbsp; chest, throat or nasal infections (such as bronchitis, pneumonia, tonsillitis, sore throat (pharyngitis) and sinusitis)</p><p>-&nbsp;&nbsp; ear infections</p><p>-&nbsp;&nbsp; skin and soft tissue infections (such as an abscess or boil)</p><p>-&nbsp;&nbsp; sexually transmitted diseases caused by organisms called chlamydia or gonorrhoea.</p><p><strong>You must talk to a doctor if you do not feel better or if you feel worse.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take AZOMYCIN:</strong></p><p>-&nbsp;&nbsp; if you/your child are allergic to azithromycin or any other macrolide antibiotic such as erythromycin or clarithromycin or any of the ingredients listed in section 6. An allergic reaction may cause skin rash or wheezing</p><p><strong>Warnings and precautions </strong></p><p>As with other macrolides, azithromycin can cause abnormal changes in the electrical activity of the heart; specifically, prolongation of the QT interval which may lead to a potentially fatal irregular heart rhythm.</p><p>Prolongation of the QT interval can lead to torsades de pointes, an abnormal heart rhythm, which can be fatal.</p><p>Patients at particular risk for developing this condition include those with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias.</p><p>Therefore, it would be prudent to avoid use in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval.</p><p>Healthcare professionals should be aware of the potential for QT interval prolongation and heart arrhythmias when prescribing or administering macrolides.</p><p>Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported. Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure.</p><p>Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Stevens - Johnson syndrome, and toxic epidermal necrolysis, have been reported rarely in patients on azithromycin therapy.</p><p><strong>If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking AZOMYCIN.</strong></p><p><strong>Talk to your doctor or pharmacist before taking AZOMYCIN if you/your child have or have had any of the following:</strong></p><p>-&nbsp;&nbsp; kidney problems<strong> </strong></p><p>-&nbsp;&nbsp; heart conditions</p><p>-&nbsp;&nbsp; diabetes</p><p>-&nbsp;&nbsp; liver problems: your doctor may need to monitor your liver function or stop the treatment&nbsp;</p><p>-&nbsp; &nbsp;myasthenia gravis (localised muscle weakness)</p><p>-&nbsp;&nbsp; if you/your child are taking any ergot derivatives such as ergotamine (used to treat migraine) as these medicines should not be taken together with <strong>AZOMYCIN</strong>.</p><p><strong>Tell your doctor immediately: </strong></p><p>-&nbsp; if you feel your heart beating in your chest or have an abnormal heartbeat or get dizzy or faint or suffer from any muscle weakness when taking <strong>AZOMYCIN</strong>.</p><p>-&nbsp; If you develop diarrhoea or loose stools during or after treatment, tell your doctor at once. Do not take any medicine to treat your diarrhoea without first checking with your doctor. If your diarrhoea continues, please inform your doctor.</p><p>-&nbsp; if you feel you are having an allergic reaction (e.g. difficulty in breathing, dizziness, swelling of the face or throat, rash, wheals, blistering). Stop taking this medicine and seek urgent medical advice.</p><p>-&nbsp; if you develop signs of liver problems (e.g. dark urine, profound loss of appetite or yellowing of the skin or whites of the eyes). Stop taking this medicine and seek urgent medical advice.</p><p>-&nbsp; if you are giving this medicine to an infant (less than 6 weeks of age) and they vomit or become irritable when fed.</p><p><strong>Other medicines and AZOMYCIN</strong></p><p>Tell your doctor or pharmacist if you/your child are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p><strong>In particular, AZOMYCIN may interact with the medicines listed below: </strong></p><p>-&nbsp;&nbsp; ergot or ergotamine, see &lsquo;Warnings and precautions&rsquo; section</p><p>-&nbsp;&nbsp; warfarin or any similar medicine to prevent blood clots</p><p>-&nbsp;&nbsp; ciclosporin (used to suppress the immune system to prevent and treat rejection of a transplanted organ or bone marrow)</p><p>-&nbsp;&nbsp; digoxin (used to treat heart failure)</p><p>-&nbsp;&nbsp; colchicine (used for gout and familial Mediterranean fever) &nbsp;</p><p>-&nbsp;&nbsp; terfenadine (for hay fever or a skin allergy)</p><p>-&nbsp;&nbsp; atorvastatin (for reducing blood cholesterol levels).</p><p>If you/your child are taking antacids for indigestion, <strong>AZOMYCIN</strong> should be taken one hour before or two hours after taking antacids.</p><p><strong>AZOMYCIN with food and drink </strong></p><p><strong>AZOMYCIN </strong>is not affected by food or drink.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines </strong></p><p><strong>AZOMYCIN</strong> is not expected to affect your ability to drive or use machines.</p><p><strong>Important information about some of the ingredients of </strong><strong>AZOMYCIN</strong><strong>:</strong></p><p>This medicine contains: Castor Sugar (sucrose), a type of sugar.</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. If you are diabetic, you may need to take this into account in your diet. May be harmful to the teeth.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take or give <strong>AZOMYCIN </strong>exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The pharmacist should have advised you whether to measure the medicine using the oral dosing syringe or the measuring cup.</p><p><strong>AZOMYCIN </strong>suspension is generally used for children under (45 kg). It may also be used in adults and older children who have difficulty swallowing capsules.</p><p><strong>AZOMYCIN </strong>is not affected by food or drink.</p><p><strong>Children under 45 kg </strong></p><p>The recommended dose in children is 10 mg for each kg of bodyweight, given as a single daily dose for 3 days.</p><p><strong>Adults and children over 45 kg </strong></p><p>The recommended dose in adults and in children over (45 kg) is 500 mg taken as a single dose, for 3 days. For some diseases such as Chlamydia the recommended dose is 1 g daily taken as a single dose. For gonorrhoea the recommended dose is azithromycin 2 g as a single oral dose together with ceftriaxone 500 mg intramuscularly as a single dose.</p><p>You should tell your doctor if you/your child have kidney or liver problems as your doctor may need to alter the normal dose.</p><p>Doctors sometimes prescribe different doses to the recommended dose. If you are still not sure, ask your doctor or pharmacist.</p><p>Always continue with the course of treatment even if you/your child feel better.</p><p>If your infection gets worse or you do not start to feel better within a few days or a new infection develops, go back and see your doctor.</p><p><strong>How to give AZOMYCIN suspension in children less than 3 years of age </strong></p><p>If your child is under three years of age or weighs up to 15 kg in bodyweight, you should measure the dose as clearly as possible using the 5 mL oral dosing syringe provided.</p><p><strong><u>Direction for Reconstitution:</u></strong></p><p><strong>Pack of 15mL:</strong> Add 7mL of water.</p><p><strong>Pack of 30mL:</strong> Add 14mL of water.</p><p>Loosen powder, add water as specified above, close the bottle and shake well to disperse <em>or</em> add water to <sup>2</sup>/<sub>3</sub> of the mark on the bottle. Close the bottle, shake well to disperse and make up to the mark. Shake well.<br /><strong>Shake well before each use.</strong></p><p><strong><u>Filling the syringe with medicine</u></strong></p><p>1. Shake the bottle before use and remove the child-proof cap.</p><p>2. Hold the syringe and remove the cap of the syringe.</p><p>3. While the bottle is sitting on a firm, flat surface, hold it steady with one hand. With the other hand insert the tip of the syringe into the bottle.</p><p>4. Slowly pull back the plunger of the syringe so that the top edge is level with the graduation mark corresponding to the quantity in the millilitres (mL) prescribed by your doctor.</p><p>5. If large bubbles can be seen in the syringe, slowly push the plunger back into the syringe. This will force the medicine back into the bottle. Repeat step 4 again.</p><p>6. Remove syringe from bottle.</p><p><strong><u>Giving the medicine using the syringe </u></strong></p><p>1. Make sure your child is supported in an upright position.</p><p>2. Put the tip of the syringe carefully into your child&rsquo;s mouth. Point the tip of the syringe towards the inside of your child&rsquo;s cheek.</p><p>3. Slowly push down the plunger of the syringe: <strong>Do not squirt it out quickly. </strong>The medicine will trickle into your child&rsquo;s mouth.</p><p>4. Allow your child some time to swallow the medicine.</p><p>5. Replace the child-proof cap on the bottle. Wash the syringe as instructed below.</p><p>6. Where daily doses of less than 5mL have been given for three days, some suspension will remain in the bottle. This remaining suspension should be discarded.</p><p><strong><u>Cleaning and storing the syringe </u></strong></p><p>1. Pull the plunger out of the syringe and wash both parts by holding under warm running water.</p><p>2. Dry the two parts. Push the plunger back into the syringe. Keep it in a clean safe place with the medicine. After you have given your child the final dose of medicine, wrap the syringe in a sheet of newspaper and put it in the rubbish bin.</p><p><strong>How to give AZOMYCIN suspension in children between 3 and 14 years of age</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Bodyweight and age</strong></p></td><td style="vertical-align:top"><p><strong>Dose and duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>15-25 kg bodyweight (3-7 years)</p></td><td style="vertical-align:top"><p>5 mL (200 mg), once daily for 3 days.</p></td></tr><tr><td style="vertical-align:top"><p>26-35 kg bodyweight (8-11 years)</p></td><td style="vertical-align:top"><p>7.5 mL (300 mg), once daily for 3 days.</p></td></tr><tr><td style="vertical-align:top"><p>36-45 kg bodyweight (12-14 years)</p></td><td style="vertical-align:top"><p>10 mL (400 mg), once daily for 3 days.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Warning: if giving this medicine to a child, ensure that while receiving the medicine he/she is supported in an upright position to avoid the risk of choking.</strong></p><p><strong>If you/your child takes more AZOMYCIN than they should</strong></p><p>If you/your child take too much <strong>AZOMYCIN </strong>they may feel unwell. Tell your doctor or contact your nearest hospital casualty department immediately. Take any remaining medicine with you.</p><p><strong>If you forget to take or give AZOMYCIN </strong></p><p>If you forget to take <strong>AZOMYCIN </strong>take it as soon as you can. Take your next dose at the right time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking AZOMYCIN </strong></p><p>If you/your child stop taking <strong>AZOMYCIN </strong>too soon, the infection may return. Take <strong>AZOMYCIN </strong>for the full time of treatment, even when you/your child begin to feel better.<strong><u> </u></strong></p><p><strong>If you have any further questions about the use of this medicine, ask your doctor or pharmacist.</strong><strong style="text-align:unset">&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines <strong>AZOMYCIN </strong>can cause side effects although not everybody gets them.</p><p><strong>Tell your doctor immediately if you experience any of the following symptoms after taking this medicine. Although they are very rare, the symptoms can be severe. </strong></p><p>-&nbsp; sudden wheeziness, difficulty in breathing, swelling of eyelids, face or lips, rash or itching (especially affecting the whole body)</p><p>-&nbsp; severe skin rash causing redness and flaking</p><p>-&nbsp; rapid or irregular heartbeat</p><p>-&nbsp; low blood pressure</p><p>-&nbsp; vomiting and diarrhoea can rarely cause dehydration. It is important to drink plenty of fluid if you experience sickness and / or diarrhoea</p><p>-&nbsp; diarrhoea may occur during, or after completing, treatment with antibiotics and could be a sign of serious bowel inflammation.</p><p>-&nbsp; Serious skin reactions:</p><p> blistering of the skin, mouth, eyes and genitals (Stevens-Johnson Syndrome (SJS))</p><p> blistering of the skin, severe skin reaction (Toxic Epidermal Necrosis (TEN))</p><p> skin rash accompanied by other symptoms such as fever, swollen glands and an increase of eosinophils (a type of white blood cell). A rash appears as small, itchy red bumps (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS))</p><p> skin eruption that is characterised by the rapid appearance of areas of red skin studded with small pustules (small blisters filled with white/yellow fluid) (Acute Generalized Exanthematous Pustulosis (AGEP)).</p><p>Stop taking azithromycin if you develop these skin symptoms and contact your doctor or seek medical attention immediately.</p><p>The most common side effects that occur when taking azithromycin are listed below. These may go away during treatment as your body adjusts to the medicine. Tell your doctor if any of these side effects continue to bother you.</p><p><strong>Very common: (may affect more than 1 in 10 people):</strong></p><p>-&nbsp; diarrhoea</p><p><strong>Common: (may affect up to 1 in 10 people): </strong></p><p>-&nbsp; headache</p><p>-&nbsp; feeling sick, being sick, indigestion</p><p>-&nbsp; low number of lymphocytes (type of white blood cells), higher number of eosinophils (type of white blood cells) and other blood changes</p><p>-&nbsp; low blood bicarbonate</p><p><strong>Uncommon: (may affect up to 1 in 100 people):</strong></p><p>-&nbsp; yeast infections of the mouth and vagina (thrush)</p><p>-&nbsp; fungal or bacterial infections such as severe sore throat, gastroenteritis</p><p>-&nbsp; breathing problems, runny nose, nose bleeds</p><p>-&nbsp; low numbers of leukocytes (type of white blood cells)</p><p>-&nbsp; allergic reactions of various severity</p><p>-&nbsp; feeling nervous</p><p>-&nbsp; sleepiness or sleeplessness (insomnia)</p><p>-&nbsp; visual disturbance</p><p>-&nbsp; feeling dizzy, ear problems, vertigo</p><p>-&nbsp; heart palpitations, chest pain</p><p>-&nbsp; constipation, wind, burping, indigestion</p><p>-&nbsp; stomach pain associated with diarrhoea and fever</p><p>-&nbsp; kidney pain, pain when urinating</p><p>-&nbsp; general loss of strength, tiredness or weakness, numbness or pins and needles</p><p>-&nbsp; swelling, swollen or painful muscles, back pain, neck pain</p><p>-&nbsp; general discomfort</p><p>-&nbsp; abnormal blood test values</p><p>-&nbsp; rash, red, dry or itchy skin, or excess sweating</p><p>-&nbsp; bleeding between periods in women</p><p>-&nbsp; testicular pain in men</p><p>-&nbsp; hot flushes.</p><p><strong>Rare: (may affect up to 1 in 1,000 people):</strong></p><p>-&nbsp; agitation</p><p>-&nbsp; skin more sensitive to sunlight than normal</p><p>-&nbsp; changes in liver function, yellowing of the skin and eyes</p><p>-&nbsp; skin eruption that is characterised by the rapid appearance of areas of red skin studded with small pustules (small blisters filled with white/yellow fluid)</p><p>-&nbsp; a delayed allergic reaction (up to several weeks after exposure) with rash and other possible symptoms such as swelling of the face, swollen glands and abnormal test results (e.g. liver tests and raised levels of some white blood cells).</p><p><strong>&nbsp;Not known: frequency cannot be estimated from the available data:</strong></p><p>-&nbsp; fits, fainting, twitching muscles</p><p>-&nbsp; aggression, anxiety, delirium, hallucinations, sleep disturbances (e.g. nightmares, night terrors)</p><p>-&nbsp; feeling hyperactive</p><p>-&nbsp; localised muscle weakness</p><p>-&nbsp; painful joints</p><p>-&nbsp; deafness, hearing loss, ringing in the ears</p><p>-&nbsp; loss of smell or altered sense of smell, loss of taste</p><p>-&nbsp; tongue discolouration</p><p>-&nbsp; inflammation of the pancreas (pancreatitis)</p><p>-&nbsp; inflammation of the kidney or kidney failure</p><p>-&nbsp; liver failure (rarely life-threatening)</p><p>-&nbsp; bruising or prolonged bleeding after injury</p><p>-&nbsp; reduction in red blood cells which can make the skin pale and cause weakness or breathlessness</p><p>-&nbsp; low blood pressure</p><p>-&nbsp; blistering of the skin, severe skin reaction</p><p>-&nbsp; abnormal electrocardiogram (ECG).</p><p><strong>&nbsp;</strong></p><p><strong><u>Reporting of side effects </u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p>&sect; <strong>Saudi</strong><strong> Arabia:</strong></p><p><strong>&nbsp; &nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p>-&nbsp;&nbsp; <strong>SFDA Call Centre:</strong> 19999</p><p>-&nbsp;&nbsp; <strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp; <strong>Website: </strong>https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other</strong><strong> GCC States:</strong></p><p>-&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp; Before reconstitution, store below 30&deg;C, in a dry place.</p><p>After reconstitution, store in a refrigerator and use within 7 days.</p><p>-&nbsp; Do not take <strong>AZOMYCIN</strong> after the expiry date which is stated on the carton and on the inner label.</p><p>-&nbsp; Do not take <strong>AZOMYCIN</strong> if you notice any visible sign of deterioration.</p><p>-&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Azithromycin.</p><p>Each teaspoonful (5mL) of the reconstituted suspension contains: Azithromycin dihydrate equivalent to azithromycin 200mg.</p><p>Other ingredients: Castor sugar, sodium phosphate tribasic, sodium benzoate, hydroxyl propyl cellulose, xanthan gum, cherry flavour permaseal, vanilla dry flavour and banana dry flavour.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                AZOMYCIN suspension is available in packs of 1 bottle (15mL or 30mL after reconstitution) each.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                20/07/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي هذا الدواء<strong> </strong>على أزيثرومايسين والذي ينتمي إلى مجموعة من المضادات الحيوية التي تعرف باسم الماكروليدات. تستعمل هذه المضادات الحيوية لعلاج حالات العدوى التي تسببها سلالات معينة من البكتيريا والكائنات الدقيقة الأخرى والتي تتضمن على:</p><p dir="RTL">-&nbsp; العدوى التي تصيب الصدر، الحلق أو الأنف (على سبيل المثال التهاب الشعب الهوائية، الالتهاب الرئوي، التهاب اللوزتين، التهاب الحلق والتهاب الجيوب الأنفية)</p><p dir="RTL">-&nbsp; العدوى التي تصيب الأذن</p><p dir="RTL">-&nbsp; العدوى التي تصيب الجلد والأنسجة الرخوة (على سبيل المثال الخراج أو الدمل)</p><p dir="RTL">-&nbsp; العدوى التي تنتقل عن طريق الاتصال الجنسي والتي تسببها كائنات دقيقة تعرف باسم الكلاميديا أو الجونوريا</p><p dir="RTL"><strong>يجب عليك التحدث إلى الطبيب المعالج على الفور إذا كنت تشعر بعدم تحسن حالتك المرضية أو أنها تزداد سوءاً.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عليك عدم تناول أزومايسين في الحالات التالية:</strong></p><p dir="RTL">-&nbsp; إذا كنت أنت تعاني أو طفلك من الحساسية تجاه أزيثرومايسين أو تجاه أياً من المضادات الحيوية من مجموعة الماكروليدات الأخرى على سبيل المثال الإريثروماسين أو كلاريثروماسين أو تجاه أياً من المواد الغير فعالة المذكورة في البند رقم 6. قد تتسبب التفاعلات التحسسية في حدوث طفح جلدي أو أزيز.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">كما هو عليه الحال مع الماكروليدات الأخرى، قد يتسبب أزيثرومايسين في حدوث عدد من التغيرات الغير طبيعية في النشاط الكهربائي للقلب، لاسيما حدوث إطالة فترة كيو تي، مما يترتب عليه حدوث عدم انتظام ضربات القلب، الأمر الذي قد يكون مهدد للحياة.</p><p dir="RTL">قد يؤدي حدوث إطالة في فترة كيو تي إلى حدوث حالة تورساد دي بوينت، وهي حالة غير طبيعية لاضطرابات نظم القلب، والتي قد تكون مهددة للحياة.</p><p dir="RTL">تشتمل فئات المرضى الأكثر عرضة لخطر حدوث ذلك على المرضى الذين يعانون من عوامل خطر على سبيل المثال المرضى الذين يعانون من إطالة فترة كيوتي، المرضى الذين يعانون من انخفاض مستويات البوتاسيوم أو المغنيسيوم في الدم، المرضى الذين يعانون من بطء ضربات القلب لديهم عن المعدل المعتاد، أو المرضى الذين يتناولون&nbsp; بعض الأدوية التي تستخدم &nbsp;لعلاج عدم انتظام ضربات القلب الغير طبيعية.</p><p dir="RTL">لذلك من الحذر تجنب استعمال أزيثرومايسين للمرضى الذين عرف عنهم أنهم يعانون من حدوث إطالة للزمن الفاصل بين موجات كيو تي، المرضى الذين يعانون من وجود ظروف صحية مستمرة تؤدي إلى اضطراب نظم القلب بالمثل نقص بوتاسيوم الدم أو نقص مغنيسيوم الدم اللذان لم يتم علاجهما بعد، بطء ضربات القلب الملحوظ سريرياً، والمرضى الذين يتناولون مضادات اضطراب نظم القلب من المجموعة 1 الفئة أي (كينيدين، بروكيناميد) أو المجموعة 3 (دوفيتيلايد، أميودارون، سوتالول).</p><p dir="RTL">قد يكون المرضى المسنين أكثر عرضة لحدوث التأثيرات الدوائية المتعلقة بالزمن الفاصل بين موجات&nbsp; كيو تي.</p><p dir="RTL">يجب على أخصائي الرعاية الصحية أن يكون على دراية تامة حول إمكانية حدوث إطالة في الزمن الفاصل بين موجات كيو تي، واضطراب نظم القلب عند وصف أو إعطاء العلاج بالماكروليدات.</p><p dir="RTL">كما تم الإبلاغ عن حالات لردود فعل تجاه الدواء تتمثل في حدوث فرط الحمضات وأعراض جهازية.</p><p dir="RTL">على الرغم من النجاح في علاج أعراض الحساسية في بداية الأمر، إلا أنه تكرر حدوث هذه الأعراض مرة أخرى بعد مرور وقت قصير من التوقف عن علاج أعراض الحساسية لدى بعض المرضى دون تناولهم المزيد من أزيثرومايسين.</p><p dir="RTL">سجل بصورة نادرة لدى بعض المرضى الذين يتناولون أزيثرومايسين حدوث تفاعلات تحسسية خطيرة والتي تتضمن وذمة وعائية، استهداف، وتفاعلات جلدية تتضمن متلازمة ستيفين-جونسون، وانحلال البشرة السمي النخري.</p><p dir="RTL"><strong>إذا كنت لست متأكداً بأن أي من هذه الحالات تنطبق عليك، استشر طبيبك &nbsp;المعالج أو الصيدلي الذي تتعامل معه قبل تناول أزومايسين.</strong></p><p dir="RTL"><strong>يرجى منك التحدث إلى طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل أن تتناول أزومايسين إذا كنت تعاني أنت أو طفلك من أي من الحالات التالية:</strong></p><p dir="RTL">-&nbsp; مشاكل في الكلى</p><p dir="RTL">-&nbsp; مشاكل قلبية</p><p dir="RTL">-&nbsp; داء السكري</p><p dir="RTL">-&nbsp; مشاكل في الكبد: قد يحتاج طبيبك المعالج إلى مراقبة وظائف الكبد لديك أو إلى إيقاف العلاج</p><p dir="RTL">-&nbsp; الوهن العضلي الوبيل (ضعف عضلي موضعي)</p><p dir="RTL">-&nbsp; إذا كنت تتناول أو طفلك يتناول أياً من مشتقات الإرجوت على سبيل المثال الإرجوتامين (يستخدم لعلاج حالات الصداع النصفي) حيث أنه يجب عدم تناول مثل هذه الأدوية بالتزامن مع <strong>أزومايسين</strong>.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج على الفور</strong>:</p><p dir="RTL">-&nbsp; &nbsp;إذا كنت تشعر بضربات قلبك على نحو غير معتاد أو اذا كنت تعاني من اضطراب في ضربات القلب أو إذا شعرت بالدوخة&nbsp; أو الإغماء أو إذا عانيت من ضعف العضلات أثناء فترة تناول <strong>أزومايسين</strong>.</p><p dir="RTL">-&nbsp; يرجى منك إخبار طبيبك المعالج على الفور إذا عانيت من الإسهال أو البراز الرخو أثناء فترة أو الانتهاء من تلقي العلاج. يجب عليك عدم تناول أية أدوية لعلاج الإسهال قبل الخضوع أولاً للفحص من قبل طبيبك المعالج. في حال استمرار الإسهال، يرجى منك إخبار طبيبك المعالج.</p><p dir="RTL">-&nbsp; إذا كنت تعاني من التفاعلات التحسسية (صعوبة في التنفس، دوخة، تورم الوجه أو الحلق، طفح جلدي، شرى، تقرحات جلدية). يرجى منك التوقف عن تناول هذا الدواء وطلب المشورة الطبية على الفور.</p><p dir="RTL">-&nbsp; إذا كان لديك علامات تدل على وجود مشاكل في الكبد (على سبيل المثال بول داكن اللون، فقدان الشهية بصورة شديدة أو اصفرار الجلد أو بياض العينين). يرجى منك التوقف عن تناول هذا الدواء وطلب المشورة الطبية على الفور.</p><p dir="RTL">-&nbsp; إذا قمت بإعطاء هذا الدواء لطفل حديث الولادة (بعمر أقل من 6 أسابيع) وعانى من التقيؤ أو هياج أثناء فترة الرضاعة.</p><p dir="RTL"><strong>تناول الأدوية الأخرى بالتزامن أزومايسين</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا تناولت أو طفلك تناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى، بما في ذلك الأدوية التي تصرف دون وصفة طبية.</p><p dir="RTL"><strong>بصفة خاصة، قد يتفاعل </strong><strong>أزومايسين</strong><strong> </strong><strong>&nbsp;مع الأدوية المذكورة أدناه:</strong></p><p dir="RTL">-&nbsp; الإرجوت أو الإرجوتامين &ndash; انظر قسم &quot;تحذيرات واحتياطات&quot;.</p><p dir="RTL">-&nbsp; الوارفارين أو الأدوية المشابهة له - &nbsp;دواء يستخدم لمنع تخثر الدم.</p><p dir="RTL">-&nbsp; سيكلوسبورين (دواء يستخدم لتثبيط الجهاز المناعي للجسم لمنع الجسم من رفض الأعضاء المزروعة أو النخاع العظمي).</p><p dir="RTL">-&nbsp; الديجوكسين ( يستخدم لعلاج حالات قصور القلب)</p><p dir="RTL">-&nbsp; كولشيسين (يستخدم لعلاج داء النقرس وحمى البحر الأبيض المتوسط العائلية)</p><p dir="RTL"><strong>-&nbsp; </strong>تيرفينادين (دواء يستخدم لعلاج حمى القش أو حساسية الجلد)</p><p dir="RTL">-&nbsp; أتورفاستاتين (لتقليل مستويات الكوليسترول في الدم).</p><p dir="RTL">إذا كنت تتناول أو طفلك يتناول مضادات الحموضة لعلاج عسر الهضم، فيجب عليك تناول <strong>أزومايسين </strong>قبل ساعة أو ساعتين من تناول مضادات الحموضة.</p><p dir="RTL"><strong>تناول أزومايسين مع الطعام والشراب</strong></p><p dir="RTL">لا يؤثر تناول الطعام أو الشراب على <strong>أزومايسين.</strong></p><p dir="RTL"><strong>الحمل، الرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعاملين معه قبل تناول هذا الدواء للحصول على المشورة الطبية، إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، &nbsp;تعتقدين بأنك حامل أو أنك تخططين لكي تصبحين حاملاً</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس من المتوقع أن يؤثر <strong>أزومايسين</strong> على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>معلومات هامة عن بعض مكونات أزومايسين</strong></p><p dir="RTL">يحتوي هذا الدواء على: السكر الناعم (سكروز) وهو أحد أنواع السكر.</p><p dir="RTL">يرجى منك استشارة طبيبك المعالج قبل تناول هذا الدواء إذا كان قد أخبرك مسبقاً بأنك تعاني من مشكلة تتمثل في عدم المقدرة على تحمل بعض أنواع السكر. &nbsp;يجب أن يؤخذ ذلك بعين الاعتبار إذا كنت تعاني من داء السكري وتتبع نظام غذائي خاص. قد يلحق الضرر بالأسنان.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك دائماً تناول أو إعطاء <strong>أزومايسين</strong> بدقة وفقاً لإرشادات طبيبك المعالج. يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه ما لم تكن متأكداً من كيفية تناول هذا الدواء.</p><p dir="RTL">يجب أن ينصحك الصيدلي الذي تتعامل معه بأن تستخدم حقنة قياس الجرعة الفموية أو كأس الجرعة المدرج لقياس مقدار الجرعة &nbsp;المطلوبة من الدواء.</p><p dir="RTL">عادة ما يستخدم معلق <strong>أزومايسين</strong> للأطفال الذين يزنون أقل من 45 كلغم. كما أنه قد يستخدم من قبل البالغون والأطفال الأكبر سناً الذين يواجهون صعوبة في ابتلاع الكبسولات.</p><p dir="RTL">لا يؤثر تناول الطعام أو الشراب على <strong>أزومايسين.</strong></p><p dir="RTL"><strong>الأطفال الذين يزنون أقل من 45 كلغم</strong></p><p dir="RTL">يبلغ مقدار الجرعة الموصى بها للأطفال 10 ملغم لكل كيلوغرام من وزن الجسم ويتم إعطاؤها على هيئة جرعة مفردة لمدة 3 أيام.</p><p dir="RTL"><strong>البالغون والأطفال الذين يزنون أكثر من 45 كلغم</strong></p><p dir="RTL">يبلغ مقدار الجرعة الموصى بها للبالغين والأطفال الذين يزنون أكثر من 45 كلغم 500 ملغم &nbsp;على هيئة جرعة مفردة مرة واحدة يومياً لمدة 3 أيام. &nbsp;</p><p dir="RTL">لبعض الأمراض مثل الكلاميديا يبلغ مقدار الجرعة الموصى بها 1 غرام يومياً وتؤخذ على هيئة جرعة مفردة . لعلاج مرض السيلان، يبلغ مقدار الجرعة الموصى بها&nbsp; 2 غرام من أزيثرومايسين بالإضافة إلى 500 ملغم من سيفترياكسون عن طريق الحقن في العضل ويؤخذ على هيئة جرعة مفردة.</p><p dir="RTL">يجب عليك إخبار طبيبك المعالج إذا كنت &nbsp;تعاني أو طفلك يعاني من المشاكل في الكلى أو الكبد حيث أن طبيبك المعالج قد يكون بحاجة إلى تعديل مقدار الجرعة الاعتيادية.</p><p dir="RTL">في بعض الأحيان قد يقوم الأطباء بوصف جرعات مختلفة من الدواء لمثل هذ الفئات من المرضى.&nbsp; يرجى منك مراجعة طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا كنت لا تزال غير متأكد أو لديك أدنى شك.</p><p dir="RTL">يجب عليك الاستمرار في اتباع المسار العلاجي الخاص بك حتى وإن شعرت أو شعر طفلك بالتحسن.</p><p dir="RTL">يرجى منك مراجعة طبيبك المعالج، في حال تدهور حالتك الصحية أو أنك لم تشعر بالتحسن خلال أيام قليلة من بدء تلقي العلاج أو في حال ظهور عدوى جديدة.</p><p dir="RTL"><strong>&nbsp;كيفية إعطاء معلق أزومايسين للأطفال بعمر أقل من 3 سنوات</strong></p><p dir="RTL">إذا كان طفلك بعمر أقل من 3 سنوات أو إذا كان وزن جسم الطفل يصل إلى 15 كلغم يجب قياس الجرعة بدقة قدر المستطاع باستخدام حقنة قياس الجرعة الفموية.</p><p dir="RTL"><strong><u>إرشادات التحضير:</u></strong></p><p dir="RTL"><strong>عبوة سعة 15 ملليلتر:</strong> أضف 7 ملليلتر من الماء.</p><p dir="RTL"><strong>عبوة سعة 30 ملليلتر:</strong> أضف 14 ملليلتر من الماء.</p><p dir="RTL">حرك المسحوق، أضف الماء كما هو محدد أعلاه، ثم أغلق الزجاجة ورجها جيداً أو أضف بعض الماء حتى ثلثي العلامة على الزجاجة ثم قم بإغلاقها ورج جيداً. أكمل إضافة الماء حتى العلامة على الزجاجة ورج جيداً.</p><p dir="RTL"><strong>قم برج الزجاجة جيداً قبل كل استعمال.</strong></p><p dir="RTL"><strong><u>تعبئة حقنة قياس الجرعة بالدواء</u></strong></p><p dir="RTL">1. &nbsp;قم برج الزجاجة قبل الاستعمال، ثم افتح الزجاجة عن طريق إزالة الغطاء المقاوم للأطفال.</p><p dir="RTL">2. &nbsp;قم بمسك حقنة قياس الجرعة وإزالة الغطاء المخصص لها.</p><p dir="RTL">3. &nbsp;ضع زجاجة الدواء على سطح ثابت ومستو، ثم امسكها بيدٍ واحدة جيداً. بعد ذلك قم بإدخال مقدمة الحقنة داخل الزجاجة بواسطة اليد الأخرى.</p><p dir="RTL">4. &nbsp;اسحب مكبس الحقنة باتجاه الأعلى ببطء حتى تصبح الحافة العلوية لمكبس الحقنة بمحاذاة العلامة المدرجة التي تعادل مقدار الجرعة الموصى به من قبل الطبيب المعالج بوحدة الملليلتر.</p><p dir="RTL">5. &nbsp;في حال لاحظت وجود فقاعات داخل الحقنة، قم بدفع مكبس الحقنة إلى الأسفل لإعادة الكمية التي تم سحبها من الدواء مجدداً إلى الزجاجة. بعد ذلك قم بإعادة خطوة رقم 4.</p><p dir="RTL">6. &nbsp;قم بإخراج الحقنة من الزجاجة.</p><p><strong><u>إعطاء الدواء باستخدام حقنة قياس الجرعة</u></strong></p><p dir="RTL">1. تأكد من أن طفلك في وضع رأسي قائم.</p><p dir="RTL">1. &nbsp;قم بوضع مقدمة حقنة قياس الجرعة بعناية وحذر في داخل فم طفلك ثم حرك مقدمة الحقنة نحو الداخل باتجاه خد الطفل.</p><p dir="RTL">2. &nbsp;ادفع ببطء مكبس الحقنة: <strong>لا تقم بإخراجها بسرعة</strong> سوف يتدفق الدواء ببطء في فم الطفل.</p><p dir="RTL">3. &nbsp;اسمح لطفلك ببعض الوقت لابتلاع الدواء.</p><p dir="RTL">4. &nbsp;قم بإعادة غطاء الدواء المقاوم للأطفال وغسل حقنة قياس الجرعة وفقاً للتعليمات المذكورة أدناه.</p><p dir="RTL">5. &nbsp;قد يصف الطبيب المعالج جرعة مقدارها أقل من 5 ملليلتر تؤخذ لمدة 3 أيام. لذلك سوف يتبقى القليل من المعلق في الزجاجة يجب التخلص من الكمية المتبقية<strong>.</strong></p><p dir="RTL"><strong><u>تنظيف حقنة قياس الجرعة وحفظها</u></strong></p><p dir="RTL">1. &nbsp;قم بسحب المكبس من الحقنة وغسل الجزئين بواسطة الماء الدافىء الجاري.</p><p dir="RTL">2. &nbsp;قم بتجفيف الجزئين جيداً ودفع &nbsp;المكبس مرة أخرى داخل الحقنة. احتفظ بالحقنة في مكان آمن ونظيف مع عبوة الدواء. بعد إعطاء الجرعة الأخيرة من الدواء &nbsp;لطفلك قم بلف الحقنة في ورقة صحيفة ووضعها في صندوق القمامة.</p><p dir="RTL"><strong>كيفية إعطاء معلق أزومايسين للأطفال بعمر يتراوح من 3 سنوات إلى 14 سنة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>العمر ووزن الجسم</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>مقدار الجرعة ومدة العلاج</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">15 -25 كلغم من وزن الجسم (3 &ndash; 7 سنوات)</p></td><td style="vertical-align:top"><p dir="RTL">5 ملليلتر (200 ملغم) مرة واحدة يومياً لمدة 3 أيام</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">26 &ndash; 35 كلغم من وزن الجسم ( 8 - 11سنة)</p></td><td style="vertical-align:top"><p dir="RTL">7,5 ملليلتر (300 ملغم) مرة واحدة يومياً لمدة 3 أيام</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">36 &ndash; 45 كلغم من وزن الجسم ( 12 - 14سنة)</p></td><td style="vertical-align:top"><p dir="RTL">10 ملليلتر (400 ملغم) مرة واحدة يومياً لمدة 3 أيام</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p><strong>تحذير: في حال إعطاء هذا الدواء لطفلك، فيجب التأكد بأنه في وضع رأسي قائم لتجنب خطر الاختناق. </strong></p><p dir="RTL"><strong>إذا تناولت أو تناول طفلك أزومايسين </strong><strong>بجرعة أكبر مما يجب</strong></p><p dir="RTL">إذا تناولت أو تناول طفلك <strong>أزومايسين </strong>بجرعة أكبر من الاعتيادية على سبيل الخطأ فقد يؤدي ذلك إلى الشعور بالتوعك. يرجى منك إخبار طبيبك المعالج أو التوجه إلى قسم الطوارئ في أقرب مستشفى على الفور. يرجى منك أخذ الكمية المتبقية من الدواء معك.</p><p dir="RTL"><strong>إذا سهوت عن تناول أو إعطاء أزومايسين</strong></p><p dir="RTL">إذا سهوت عن تناول إحدى الجرعات من <strong>أزومايسين</strong> فيجب عليك تناولها في أسرع&nbsp; وقت ممكن حال تذكرها. بعد ذلك قم بتناول الجرعة التالية في موعدها الصحيح.</p><p dir="RTL">يجب عدم تناول جرعة مضاعفة لتعويض الجرعة التي قد سهوت عن تناولها.</p><p dir="RTL"><strong>إذا توقفت عن تناول أزومايسين</strong></p><p dir="RTL">إذا توقفت أو توقف طفلك عن تناول <strong>أزومايسين</strong> في مرحلة مبكرة من العلاج فقد يعاود ظهور العدوى مرة أخرى. يجب تناول <strong>أزومايسين</strong> وإتمام الدورة العلاجية كاملة كما وصفت لك حتى وإن كنت تشعر أو شعر طفلك بالتحسن.</p><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول استعمال هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يؤدي <strong>أزومايسين</strong>، إلى حدوث تأثيرات جانبية، ولكنها قد لا تحدث لكل شخص.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج على الفور، إذا كنت تعاني من حدوث أياً من الأعراض التالية بعد تناول هذا الدواء. على الرغم أنها تحدث بصورة نادرة جداً، فقد تكون هذه الأعراض شديدة.</strong></p><p dir="RTL">-&nbsp; حدوث أزيز مفاجئ، صعوبة في التنفس، تورم جفون العينين، الوجه أو الشفتين، طفح جلدي أو حكة (وبصفة خاصة التي تؤثر على الجسم بأكمله)</p><p dir="RTL">-&nbsp; طفح جلدي شديد الذي يؤدي إلى إحمرار أو تقشر الجلد</p><p dir="RTL">-&nbsp; تسارع أو عدم انتظام ضربات القلب</p><p dir="RTL">-&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp; تقيؤ وإسهال، نادراً ما قد يسبب في حدوث جفاف. من المهم تناول كمية كافية من السوائل إذا كنت تشعر بالتوعك / أو الإسهال.</p><p dir="RTL">-&nbsp; الإسهال الذي قد يحدث أثناء فترة&nbsp; أو بعد انتهاء تلقي العلاج باستخدام المضادات الحيوية وقد يكون ذلك من علامات حدوث التهاب خطير في الأمعاء.&nbsp;</p><p dir="RTL">- تفاعلات جلدية خطيرة:</p><p dir="RTL">&nbsp;&nbsp;&nbsp; تقرح الجلد، الفم، العينين والأعضاء التناسلية (متلازمة ستيفن جونسون)</p><p dir="RTL">&nbsp;&nbsp;&nbsp; تقرح الجلد، تفاعلات جلدية شديدة (انحلال البشرة السمي التنخري)</p><p dir="RTL">&nbsp;&nbsp;&nbsp; طفح جلدي مصحوب بأعراض أخرى مثل الحمى، تورم الغدد وزيادة الحمضات (نوع من خلايا الدم البيضاء). يظهر الطفح الجلدي على شكل نتوءات حمراء صغيرة مصحوبة بحكة (التفاعلات الدوائية مع فرط الحمضات والأعراض الجهازية)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي والذي يتميز بظهور مناطق حمراء في الجلد بشكل سريع&nbsp; تكون مصحوبة بظهور بثور صغيرة (بثور صغيرة مملوءة بسائل أبيض / أصفر) (البثار الطفحي المعمم الحاد).</p><p dir="RTL">في حال كنت تعاني أي من هذه الأعراض الجلدية، يرجى منك التوقف عن تناول أزيثرومايسين والتواصل مع طبيبك المعالج أو الحصول على الرعاية الطبية على الفور.</p><p dir="RTL">التأثيرات الجانبية الأكثر شيوعاً التي تحدث خلال فترة تناول أزيثرومايسين تم ذكرها أدناه. قد تختفي هذه التأثيرات الجانبية خلال فترة العلاج بعد أن يتأقلم الجسم على الدواء. يرجى منك إخبار طبيبك المعالج في حال زيادة حدة أياً من هذه التأثيرات الجانبية:</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة جداً (قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">-&nbsp; إسهال</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">-&nbsp; صداع</p><p dir="RTL">-&nbsp; الشعور بالإعياء، التوعك، عسر الهضم</p><p dir="RTL">-&nbsp; انخفاض تعداد الخلايا الليمفاوية (أحد أنواع خلايا الدم البيضاء)، ارتفاع تعداد الحمضات (أحد أنواع خلايا الدم البيضاء) وتغيرات أخرى في الدم</p><p dir="RTL">-&nbsp; انخفاض البيكربونات&nbsp;في الدم</p><p dir="RTL"><strong>التأثيرات الجانبية الغير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><p dir="RTL">-&nbsp; عدوى فطرية في الفم والمهبل (داء القلاع)</p><p dir="RTL">-&nbsp; العدوى الناجمة البكتيريا أو الفطريات على سبيل المثال احتقان شديد في الحلق، التهاب المعدة والأمعاء</p><p dir="RTL">-&nbsp; مشاكل في التنفس، سيلان الأنف، نزيف من الأنف</p><p dir="RTL">-&nbsp; انخفاض تعداد كريات الدم البيضاء (أحد أنواع خلايا الدم البيضاء)</p><p dir="RTL">-&nbsp; تفاعلات تحسسية متعددة الشدة</p><p dir="RTL">-&nbsp; الشعور بالتوتر</p><p dir="RTL">-&nbsp; النعاس أو عدم القدرة على النوم (أرق)</p><p dir="RTL">-&nbsp; اضطرابات بصرية</p><p dir="RTL">-&nbsp; الشعور بالدوخة، مشاكل في الأذنين، الشعور بالدوار</p><p dir="RTL">-&nbsp; خفقان القلب، ألم في الصدر</p><p dir="RTL">-&nbsp; إمساك، ريح، التجشؤ، عسر الهضم</p><p dir="RTL">-&nbsp; &nbsp;ألم في المعدة مصحوباً بإسهال وحمى</p><p dir="RTL">-&nbsp; ألم في الكلى، الشعور بالألم أثناء التبول</p><p dir="RTL">-&nbsp; ضعف عام في الصحة، الشعور بالتعب أو الوهن، شعور بالتخدر أو بالوخز كوخز الإبر والدبابيس</p><p dir="RTL">-&nbsp; تورم، تورم أو ألم في العضل، الم في الظهر، ألم في الرقبة</p><p dir="RTL">-&nbsp; تدهورعام في الصحة</p><p dir="RTL">-&nbsp; نتائج غير طبيعية لقيم فحوصات الدم</p><p dir="RTL">-&nbsp; طفح جلدي، إحمرار وجفاف الجلد مصحوباً بحكة، فرط التعرق</p><p dir="RTL">-&nbsp; حدوث نزيف ما بين الدورات الشهرية لدى النساء</p><p dir="RTL">-&nbsp; ألم الخصية عند الرجال</p><p dir="RTL">-&nbsp; الهبات الساخنة</p><p dir="RTL"><strong>التأثيرات الجانبية النادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص)</strong></p><p dir="RTL">-&nbsp; الهياج</p><p dir="RTL">-&nbsp; زيادة حساسية الجلد تجاه أشعة الشمس بصورة أكثر من المعتاد</p><p dir="RTL">-&nbsp; تغيرات في وظائف الكبد، اصفرار لون الجلد أو العينين</p><p dir="RTL">-&nbsp; طفح جلدي الذي يتمثل في ظهور احمرار في مناطق من الجلد بصورة سريعة مصحوباً ببثور صغيرة (بثور صغيرة مملوءة بسائل أبيض / أصفر)</p><p dir="RTL">-&nbsp; حدوث تفاعلات تحسسية بصورة متأخرة (لمدة تصل إلى عدة أسابيع من التعرض للدواء) مصحوباً بطفح جلدي والأعراض الأخرى المحتمل حدوثها على سبيل المثال تورم الوجه، تورم الغدد ونتائج غير طبيعية للفحوصات المختبرية (على سبيل المثال فحوصات الكبد وارتفاع مستويات بعض خلايا الدم البيضاء).</p><p dir="RTL"><strong>غير معروفة</strong><strong>: </strong><strong>لا يمكن تقدير </strong><strong>معدل تكرار حدوثها من البيانات المتاحة</strong></p><p dir="RTL">-&nbsp; اختلاجات، إغماء، الشعور بالوخز في العضلات</p><p dir="RTL">-&nbsp; العدوانية، القلق، هذيان، هلوسة، اضطراب في النوم (على سبيل المثال كوابيس، هلع النوم)</p><p dir="RTL">-&nbsp; الشعور بالنشاط المفرط</p><p dir="RTL">-&nbsp; ضعف العضلات الموضعي</p><p dir="RTL">-&nbsp; ألم في المفاصل</p><p dir="RTL">-&nbsp; فقدان حاسة السمع، ضعف في حاسة السمع أو طنين في الأذنين</p><p dir="RTL">-&nbsp; فقدان أو تغير في حاسة الشم، فقدان حاسة التذوق</p><p dir="RTL">-&nbsp; تغير لون اللسان</p><p dir="RTL">-&nbsp; التهاب البنكرياس</p><p dir="RTL">-&nbsp; التهاب الكلى أو قصور كلوي</p><p dir="RTL">-&nbsp; قصور الكبد (قد تكون مهددة للحياة بصورة نادرة)</p><p dir="RTL">-&nbsp; ظهور كدمات أو حدوث نزيف لفترة طويلة بعد التعرض للإصابة</p><p dir="RTL">-&nbsp; انخفاض مستويات خلايا الدم الحمراء التي من الممكن أن تؤدي إلى شحوب لون الجلد والشعور بالضعف أو ضيق في التنفس</p><p dir="RTL">-&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp; تقرحات جلدية، تفاعلات جلدية شديدة</p><p dir="RTL">-&nbsp; تخطيط القلب الكهربائي الغير الطبيعي</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong></p><p dir="RTL">يرجى منك التحدث إلى طبيبك المعالج الصيدلي الذي تتعامل معه أو الممرض، في حال حدوث أياً من التأثيرات الجانبية، بما في ذلك أية تأثيرات جانبية يحتمل حدوثها لم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية بصورة مباشرة عن طريق:</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>مركز الاتصال الموحد:</strong> 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; ا<strong>لموقع الإلكتروني:</strong> /https://ade.sfda.gov.sa</p><p dir="RTL">&sect;&nbsp;&nbsp; <strong>دول الخليج العربي الأخرى:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp; الرجاء الاتصال بجهات الوطنية في كل دولة</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">-&nbsp; قبل التحضير، يحفظ في درجة حرارة أقل من 30 &ordm;م، في مكان جاف.<br />بعد التحضير، يحفظ في الثلاجة ويستعمل خلال 7 أيام.</p><p dir="RTL">-&nbsp; يجب عدم تناول <strong>أزومايسين</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة والملصق الداخلي للزجاجة.</p><p dir="RTL">-&nbsp; يجب عدم تناول <strong>أزومايسين</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">-&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أزيثرومايسين. تحتوي كل ملعقة صغيرة (5 ملليلتر) من المعلق بعد تحضيره على: أزيثرومايسين ثنائي الهيدرات بما يعادل 200 ملغم من أزيثرومايسين.</p><p dir="RTL">المواد الأخرى: السكر الناعم، فوسفات الصوديوم ثلاثي القاعدة، بنزوات الصوديوم، هيدروكسي بروبيل السليلوز، صمغ الزانثان، نكهة الكرز، نكهة الفانيليا الجافة ونكهة الموز الجافة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر معلق <strong>أزومايسين </strong>في عبوات تحتوي كلاً منها على زجاجة واحدة (سعة 15 ملليلتر أو 30 ملليلتر بعد التحضير).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            20/07/2022م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azomycin 200mg/5mL Powder for Oral Suspension  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each teaspoonful (5mL) contains:
Item No.	Material Name	Scale (mg/5mL)
		
	Active Ingredient:	
1.		Azithromycin 	200.000
	Used: Azithromycin Dihydrate	210.000 *
		
	Inactive Ingredients:	
1.		Sodium phosphate tribasic 	18.000
2.		Sodium benzoate 	15.000
3.		Hydroxyl propyl cellulose 	2.500
4.		Xanthan gum 	2.500
5.		Cherry flavour permaseal 	15.000
6.		Vanilla dry flavour 	33.340
7.		Banana dry flavour 	25.000
8.		Castor sugar **	3862.660

* Azithromycin 200mg equivalent to 210mg of Azithromycin Dihydrate 
** Quantity of Castor Sugar may vary to adjust the quantity (desired potency) of Azithromycin and Sodium benzoate.
Powder for Oral Suspension filled into bottles with 4.184g/5mL either for 15mL or 30mL (when reconstituted) 
Reconstitution 
	For 15mL pack: 12.55g powder to be reconstituted with 7mL of water to prepare 15mL of suspension 
	For 30mL pack: 25.10g powder to be reconstituted with 14mL of water to prepare 30mL of suspension 

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Oral Suspension 
Description: White to off-white fine crystalline, free flowing powder with fruity odour. 
Appearance of reconstituted suspension: Homogeneous, white to off-white suspension with fruity odour and sweet agreeable, with slight bitter after taste.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azithromycin is indicated for the treatment of the following infections when known or likely to be due to one or more susceptible microorganisms (see section 5.1):</p><p>&sect; bronchitis</p><p>&sect; community-acquired pneumonia</p><p>&sect; sinusitis</p><p>&sect; pharyngitis/tonsillitis (see section 4.4 regarding streptococcal infections)</p><p>otitis media</p><p>&sect; skin and soft tissue infections</p><p>&sect; uncomplicated genital infections due to&nbsp;<em>Chlamydia trachomatis and Neisseria gonorrhoeae.</em></p><p>Considerations should be given to official guidance regarding the appropriate use of antibacterial agents</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong><strong>:</strong></p><p><strong>Azomycin</strong> should be given as a single daily dose.</p><p><strong>Azomycin</strong> Suspension can be taken with food.</p><p><strong>Children over 45 kg body weight and&nbsp;adults, including elderly patients</strong>: The total dose of azithromycin is 1500 mg which should be given over three days (500 mg once daily).</p><p>In uncomplicated genital infections due to&nbsp;<em>Chlamydia trachomatis</em>, the dose is 1000 mg as a single oral dose. For susceptible&nbsp;<em>Neisseria gonorrhea</em>&nbsp;the recommended dose is 2000mg of azithromycin as a single dose together with 500 mg of ceftriaxone intramuscularly as a single dose according to local clinical treatment guidelines. For patients who are allergic to penicillin and/or cephalosporins, prescribers should consult local treatment guidelines.</p><p><strong>The Elderly: </strong></p><p>The same dosage as in adult patients is used in the elderly. However, since elderly patients can be patients with ongoing proarrhythmic conditions a particular caution is recommended due to the risk of developing cardiac arrhythmia and torsades de pointes (see section 4.4).</p><p><strong>Paediatric population </strong></p><p><strong>In children under 45 kg body weight</strong>: <strong>Azomycin</strong> Suspension should be used for children under 45 kg. There is no information on children less than 6 months of age. The dose in children is 10mg/kg as a single daily dose for 3 days:</p><p><em>Up to 15 kg (less than 3 years):</em>&nbsp;Measure the dose as closely as possible using the measuring dropper provided.&nbsp;</p><p><em>For children weighing more than 15 kg</em>, <strong>Azomycin</strong> Suspension should be administered using teaspoon according to the following guidance:</p><p>&sect; 15-25 kg (3-7 years): 5 ml (200 mg), once daily for 3 days.</p><p>&sect; 26-35 kg (8-11 years): 7.5 ml (300 mg), once daily for 3 days.</p><p>&sect; 36-45 kg (12-14 years): 10 ml (400 mg), once daily for 3 days.</p><p><strong>Over 45 kg: Dose as per adults.</strong></p><p>See section 6.5 for appropriate pack size to use depending on age/body weight of child.</p><p>The specially supplied measure should be used to administer azithromycin suspension to children.</p><p><strong>Renal impairment</strong>:</p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR 10 - 80 ml/min). Caution should be exercised when azithromycin is administered to patients with severe renal impairment (GFR &lt; 10 ml/min) (see section 4.4 and section 5.2).</p><p><strong>Hepatic impairment:</strong></p><p>Since azithromycin is metabolised in the liver and excreted in the bile, the drug should not be given to patients suffering from severe liver disease. No studies have been conducted regarding treatment of such patients with azithromycin (see section 4.4).</p><p><strong><u>Method of administration</u></strong></p><p><strong>Azomycin</strong> Suspension is for oral administration only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to azithromycin, erythromycin or any of the macrolide or ketolide antibiotics, or to any of the excipients (listed in section 6.1).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Hypersensitivity </u></strong></p><p>As with erythromycin and other macrolides, rare serious allergic reactions, including angioneurotic oedema and anaphylaxis (rarely fatal), Dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) (rarely fatal) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and required a longer period of observation and treatment.</p><p>If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.</p><p><strong><u>Hepatotoxicity </u></strong></p><p>Since the liver is the principal route of elimination for azithromycin, the use of azithromycin should be undertaken with caution in patients with significant hepatic disease. Cases of fulminant hepatitis potentially leading to life-threatening liver failure have been reported with azithromycin (see section 4.8). Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products.</p><p>Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur.</p><p>In case of signs and symptoms of liver dysfunction, such as rapid developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy, liver function tests/ investigations should be performed immediately. Azithromycin administration should be stopped if liver dysfunction has emerged.</p><p><strong><u>Infantile hypertrophic pyloric stenosis (IHPS) </u></strong></p><p>Following the use of azithromycin in neonates (treatment up to 42 days of life), infantile hypertrophic pyloric stenosis (IHPS) has been reported. Parents and caregivers should be informed to contact their physician if vomiting or irritability with feeding occurs.</p><p><strong><u>Ergot derivatives </u></strong></p><p>In patients receiving ergot derivatives, ergotism has been precipitated by co-administration of some macrolide antibiotics. There are no data concerning the possibility of an interaction between ergot and azithromycin. However, because of the theoretical possibility of ergotism, azithromycin and ergot derivatives should not be co-administered.</p><p><strong><u>Superinfection</u></strong></p><p>As with any antibiotic preparation, observation for signs of superinfection with non-susceptible organisms, including fungi is recommended.</p><p><strong><u>Clostridium difficile associated diarrhoea </u></strong></p><p><em>Clostridium difficile </em>associated diarrhoea (CDAD) has been reported with the use of nearly all antibacterial agents, including azithromycin, and may range in severity form mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <em>C difficile. </em></p><p><em>C. difficile </em>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <em>C. difficile </em>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.</p><p><strong><u>Renal impairment </u></strong></p><p>In patients with severe renal impairment (GFR &lt;10 ml/min) a 33% increase in systemic exposure to azithromycin was observed (see section 5.2).</p><p><strong><u>Prolongation of the QT interval </u></strong></p><p>Prolonged cardiac repolarisation and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with other macrolides, including azithromycin. (see section 4.8) The following situations may lead to an increased risk for ventricular arrhythmias (including torsades de pointes) which can lead to cardiac arrest (possibly fatal). Azithromycin should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients) such as patients:</p><p>With congenital or documented QT prolongation</p><p>&sect; Currently receiving treatment with other active substances known to prolong QT interval such as antiarrhythmics of Class IA (quinidine and procainamide) and III, (dofetilide, amiodarone and sotalol), cisapride and terfenadine, antipsychotic agents such as pimozide, antidepressants such as citalopram; and fluoroquinolones such as moxifloxacin and levofloxacin.</p><p>&sect; With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesemia</p><p>&sect; With clinically relevant bradycardia, cardiac arrhythmia or severe cardiac insufficiency.</p><p>&sect; Elderly patients: elderly patients may be more susceptible to drug-associated effects on the QT interval</p><p><strong><u>Myasthenia gravis </u></strong></p><p>Exacerbations of the symptoms of myasthenia gravis and new onset of myasthenia syndrome have been reported in patients receiving azithromycin therapy (see section 4.8).</p><p><strong><u>Streptococcal infections </u></strong></p><p>Penicillin is usually the first choice for treatment of pharyngitis/tonsillitis due to Streptococcus pyogenes and also for prophylaxis of acute rheumatic fever. Azithromycin is in general effective against streptococcus in the oropharynx, but no data are available that demonstrate the efficacy of azithromycin in preventing acute rheumatic fever.</p><p><strong><u>Paediatric population</u></strong></p><p>Safety and efficacy for the prevention or treatment of Mycobacterium Avium complex MAC in children have not been established.</p><p><strong><u>Diabetes </u></strong></p><p>Caution in diabetic patients as the suspension contains sugar. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p><p><strong>Azomycin</strong> Suspension is for oral administration only</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Antacids</strong>: When studying the effect of simultaneously administered antacid on the pharmacokinetics of azithromycin, no overall change has been observed in the bioavailability, although the peak concentrations of azithromycin measured in the plasma fell by 24%. In patients receiving azithromycin and antacids, azithromycin should be taken at least 1 hour before or 2 hours after the antacid. Co-administration of azithromycin prolonged release granules for oral suspension with a single dose of 20 ml co-magaldrox (aluminium hydroxide and magnesium hydroxide) did not affect the rate and extent of azithromycin absorption.</p><p><strong>Cetirizine:</strong>&nbsp;In healthy volunteers, co-administration of a 5-day regimen of azithromycin with 20 mg cetirizine at steady-state resulted in no pharmacokinetic interaction and no significant changes in the QT interval.</p><p><strong>Didanosine</strong>&nbsp;<em>(Dideoxyinosine)</em>: Co-administration of 1200 mg/day azithromycin with 400 mg/day didanosine in six HIV-positive subjects did not appear to affect the steady-state pharmacokinetics of didanosine as compared to placebo.</p><p><strong>Digoxin and colchicine</strong>: concomitant administration of macrolide antibiotics, including azithromycin, with P-glycoprotein substrates such as digoxin and colchicine, has been reported to result in increased serum levels of the P-glycoprotein substrate. Therefore, if azithromycin and P-glycoprotein substrates such as digoxin are administered concomitantly, the possibility of elevated serum digoxin concentrations should be considered. Clinical monitoring, and possibly serum digoxin levels, during treatment with azithromycin and after its discontinuation are necessary.</p><p><strong>Zidovudine:&nbsp;</strong>Single 1000 mg doses and multiple 1200 mg or 600 mg doses of azithromycin had little effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of azithromycin increased the concentrations of phosphorylated zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients.</p><p>Azithromycin does not interact significantly with the hepatic cytochrome P450 system. It is not believed to undergo the pharmacokinetic drug interactions as seen with erythromycin and other macrolides. Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex does not occur with azithromycin.</p><p><strong>Ergot derivatives:</strong>&nbsp;Due to the theoretical possibility of ergotism, the concurrent use of azithromycin with ergot derivatives is not recommended (see section 4.4).</p><p>Pharmacokinetic studies have been conducted between azithromycin and the following drugs known to undergo significant cytochrome P450 mediated metabolism.</p><p><strong>Atorvastatin:</strong>&nbsp;Co-administration of atorvastatin (10 mg daily) and azithromycin (500 mg daily) did not alter the plasma concentrations of atorvastatin (based on a HMG CoA-reductase inhibition assay). However, post-marketing cases of rhabdomyolysis in patients receiving azithromycin with statins have been reported.</p><p><strong>Carbamazepine</strong>: In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant azithromycin.</p><p><strong>Cimetidine</strong>: In a pharmacokinetic study investigating the effects of a single dose of cimetidine, given 2 hours before azithromycin, on the pharmacokinetics of azithromycin, no alteration of azithromycin pharmacokinetics was seen.</p><p><strong>Coumarin-type oral anticoagulants:</strong>&nbsp;In a pharmacokinetic interaction study, azithromycin did not alter the anticoagulant effect of a single dose of 15mg warfarin administered to healthy volunteers. There have been reports received in the post-marketing period of potentiated anticoagulation subsequent to co-administration of azithromycin and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when azithromycin is used in patients receiving coumarin-type oral anticoagulants.</p><p><strong>Ciclosporin:&nbsp;</strong>In a pharmacokinetic study with healthy volunteers who were administered a 500 mg/day oral dose of azithromycin for 3 days and were then administered a single 10 mg/kg oral dose of ciclosporin, the resulting ciclosporin C<sub>max</sub>and AUC<sub>0-5&nbsp;</sub>were found to be significantly elevated (by 24% and 21% respectively), however no significant changes were seen in AUC<sub>0-&infin;</sub>. Consequently, caution should be exercised before considering concurrent administration of these drugs. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</p><p><strong>Efavirenz:</strong>&nbsp;Co-administration of a single dose of 600mg azithromycin and 400 mg efavirenz daily for 7 days did not result in any clinically significant pharmacokinetic interactions.</p><p><strong>Fluconazole:</strong>&nbsp;Co-administration of a single dose of 1200 mg azithromycin did not alter the pharmacokinetics of a single dose of 800 mg fluconazole. Total exposure and half-life&nbsp;of azithromycin were unchanged by the co-administration of fluconazole, however, a clinically insignificant decrease in C<sub>max</sub>&nbsp;(18%) of azithromycin was observed.</p><p><strong>Indinavir:</strong>&nbsp;Co-administration of a single dose of 1200 mg azithromycin had no statistically significant effect on the pharmacokinetics of indinavir administered as 800 mg three times daily for 5 days.</p><p><strong>Methylprednisolone:&nbsp;</strong>In a pharmacokinetic interaction study in healthy volunteers, azithromycin had no significant effect on the pharmacokinetics of methylprednisolone.</p><p><strong>Midazolam</strong><em>:&nbsp;</em>In healthy volunteers, co-administration of 500 mg/day azithromycin for 3 days did not cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single dose of 15 mg midazolam.</p><p><strong>Nelfinavir:&nbsp;</strong>Co-administration of azithromycin (1200 mg) and nelfinavir at steady state (750 mg three times daily) resulted in increased azithromycin concentrations. No clinically significant adverse effects were observed and no dose adjustment was required.</p><p><strong>Rifabutin:&nbsp;</strong>Co-administration of azithromycin and rifabutin did not affect the serum concentrations of either drug. Neutropenia was observed in subjects receiving concomitant treatment of azithromycin and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with azithromycin has not been established (see section 4.8.).</p><p><strong>Sildenafil:</strong>&nbsp;In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC and C<sub>max</sub>, of sildenafil or its major circulating metabolite.</p><p><strong>Terfenadine:&nbsp;</strong>Pharmacokinetic studies have reported no evidence of an interaction between azithromycin and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however there was no specific evidence that such an interaction had occurred.</p><p><strong>Theophylline:&nbsp;</strong>There is no evidence of a clinically significant pharmacokinetic interaction when azithromycin and theophylline are co-administered to healthy volunteers.</p><p><strong>Triazolam</strong><em>:&nbsp;</em>In 14 healthy volunteers, co-administration of 500mg azithromycin on Day 1 and 250 mg on Day 2 with 0.125 mg triazolam on Day 2 had no significant effect on any of the pharmacokinetic variables for triazolam compared to triazolam and placebo.</p><p><strong>Trimethoprim/sulfamethoxazole:</strong>&nbsp;Co-administration of trimethoprim/sulfamethoxazole DS (160 mg/800 mg) for 7 days with 1200mg azithromycin on Day 7 had no significant effect on peak concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole. Azithromycin serum concentrations were similar to those seen in other studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>There are no adequate data from the use of azithromycin in pregnant women. In reproduction toxicity studies in animals azithromycin was shown to pass the placenta, but no teratogenic effects were observed. The safety of azithromycin has not been confirmed with regard to the use of the active substance during pregnancy. Therefore azithromycin should only be used during pregnancy if the benefit outweighs the risk.</p><p><strong><u>Breast-feeding</u></strong></p><p>Limited information available from published literature indicates that azithromycin is present in human milk at an estimated highest median daily dose of 0.1 to 0.7 mg/kg/day. No serious adverse effects of azithromycin on the breast-fed infants were observed. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from azithromycin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><strong><u>Fertility </u></strong></p><p>In fertility studies conducted in rats, reduced pregnancy rates were noted following administration of azithromycin. The relevance of this finding to humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence to suggest that azithromycin may have an effect on a patient&#39;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azithromycin is well tolerated with a low incidence of side effects.</p><p>The section below lists the adverse reactions identified through clinical trial experience and post-marketing surveillance by system organ class and frequency. Adverse reactions identified from post-marketing experience are included in italics. The frequency grouping is defined using the following convention: Very common (&ge;1/10); Common (&ge; 1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge; 1/10,000 to &lt;1/1,000); Very Rare (&lt; 1/10,000); and Not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><strong>Adverse reactions possibly or probably related to azithromycin based on clinical trial experience and post-marketing surveillance:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:648px"><tbody><tr><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong>Very Common </strong></p><p><strong>(&ge;1/10) </strong></p></td><td style="vertical-align:top"><p><strong>Common </strong></p><p><strong>(&ge;1/100 to &lt;1/10) </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon </strong></p><p><strong>(&ge;1/1000 to </strong></p><p><strong>&lt; 1/100) </strong></p></td><td style="vertical-align:top"><p><strong>Rare (&ge; 1/10,000 to &lt;1/1,000) </strong></p></td><td style="vertical-align:top"><p><strong>Very Rare </strong></p><p><strong>(&lt;1/10,000) </strong></p></td><td style="vertical-align:top"><p><strong>Frequency Not Known </strong></p><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and Infestations </strong></p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Candidiasis</p><p>Vaginal infection</p><p>Pneumonia</p><p>Fungal infection</p><p>Bacterial infection</p><p>Pharyngitis</p><p>Gastroenteritis</p><p>Respiratory disorder</p><p>Rhinitis</p><p>Oral candidiasis</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Pseudomembranous colitis (see section 4.4)</p><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and Lymphatic System Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Leukopenia Neutropenia</p><p>Eosinophilia</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Angioedema</p><p>Hypersensitivity</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Anaphylactic reaction (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition </strong></p><p><strong>Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Anorexia</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Nervousness, Insomnia</p></td><td style="vertical-align:top"><p>Agitation</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Aggression</p><p>Anxiety</p><p>Delirium</p><p>Hallucination</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Headache</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Dizziness</p><p>Somnolence</p><p>Dysgeusia</p><p>Paraesthesia</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Syncope, convulsion Hypoestheia</p><p>Psychomotor hyperactivity Anosmia, Ageusia</p><p>Parosmia, Myasthenia gravis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Visual impairment</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and Labyrinth Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Ear disorder</p><p>Vertigo</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Hearing impairment</p><p>including deafness and/or tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Palpitations</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Torsades de pointes (see section 4.4) Arrhythmia (see section 4.4) including ventricular tachycardia</p><p>Electrocardiogram QT prolonged (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Hot flush</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Hypotension</p><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Respirator, thoracic and mediastinal disorders </strong></p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Dyspnoea,</p><p>Epistaxis</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders </strong></p></td><td style="vertical-align:top"><p>Diarrhoea</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Vomiting Abdominal pain</p><p>Nausea</p></td><td style="vertical-align:top"><p>Constipation</p><p>Flatulence</p><p>Dyspepsia,</p><p>Gastritis</p><p>Dysphagia</p><p>Abdominal distension</p><p>Dry mouth</p><p>Eructation</p><p>Mouth ulceration</p><p>Salivary hypersecretion</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Pancreatitis</p><p>Tongue discolouration</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Hepatic function abnormal</p><p>Jaundice cholestatic</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Hepatic failure (which has rarely resulted in death) (see section 4.4) Hepatitis fulminant Hepatic necrosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p><p>Urticaria,</p><p>Dermatitis</p><p>Dry skin</p><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Acute Generalized Exanthematous Pustulosis (AGEP)*&sect;,</p><p>Drug reaction with eosinophilia and systemic symptoms (see section 4.4),</p><p>Photosensitivity reaction</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>SJS</p><p>TEN</p><p>Erythema multiforme</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and Connective Tissue Disorders </strong></p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Osteoarthritis, Myalgia</p><p>Back pain</p><p>Neck pain</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Arthralgia</p><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and Urinary Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Dysuria</p><p>Renal pain</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Renal failure acute</p><p>Nephritis interstitial</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Metrorrhagia, Testicular disorder</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions </strong></p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Oedema</p><p>Asthenia</p><p>Malaise</p><p>Fatigue</p><p>Face edema</p><p>Chest pain</p><p>Pyrexia</p><p>Pain</p><p>Peripheral oedema</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations </strong></p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Lymphocyte count decreased Eosinophil count increased</p><p>Blood bicarbonate decreased</p><p>Basophils increased</p><p>Monocytes increased Neutrophils</p><p>increased</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p><p>Alanine aminotransferase increased</p><p>Blood bilirubin increased</p><p>Blood urea increased</p><p>Blood creatinine increased</p><p>Blood potassium abnormal</p><p>Blood alkaline phosphatase increased</p><p>Chloride increased</p><p>Glucose increased platelets increased</p><p>Hematocrit decreased Bicarbonate increased abnormal sodium</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p>*ADR identified post-marketing</p><p>&sect;ADR frequency represented by the estimated upper limit of the 95% confidence interval calculated using the &ldquo;Rule of 3&rdquo;.</p><p><strong>Adverse reactions possibly or probably related to Mycobacterium Avium Complex prophylaxis and treatment based on clinical trial experience and post-marketing surveillance. These adverse reactions differ from those reported with immediate release or the prolonged release formulations, either in kind or in frequency:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong>Very Common </strong></p><p><strong>(&ge;1/10) </strong></p></td><td style="vertical-align:top"><p><strong>Common </strong></p><p><strong>(&ge;1/100 to &lt;1/10) </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon </strong></p><p><strong>(&ge;1/1000 to &lt; 1/100) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Anorexia</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Dizziness Headache Paraesthesia</p><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Hypoesthesia</p><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Visual impairment</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and Labyrinth Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Deafness</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Hearing impaired</p><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders </strong></p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>Abdominal pain</p><p>Nausea</p><p>Flatulence</p><p>Abdominal discomfort</p><p>Loose stools</p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Hepatitis</p><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p></td><td style="vertical-align:top"><p>SJS</p><p>Photosensitivity reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and Connective Tissue Disorders </strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Arthralgia</p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p>Fatigue</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia</p><p>Malaise</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of side effects </u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p>&sect; <strong>Saudi</strong><strong> Arabia:</strong></p><p><strong>&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p>-&nbsp;&nbsp; <strong>SFDA Call Centre:</strong> 19999</p><p>-&nbsp;&nbsp; <strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp; <strong>Website: </strong>https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other</strong><strong> GCC States:</strong></p><p>-&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. In the event of overdosage, general symptomatic and supportive measures are indicated as required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General properties</strong></p><p>Pharmacotherapeutic group: Antibacterials for systemic use. ATC code: J01FA10</p><p><strong><u>Mode of action:</u></strong></p><p>Azithromycin is a macrolide antibiotic belonging to the azalide group. The molecule is constructed by adding a nitrogen atom to the lactone ring of erythromycin A. The chemical name of azithromycin is 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A. The molecular weight is 749.0. Azithromycin binds to the 23S rRNA of the 50S ribosomal subunit. It blocks protein synthesis by inhibiting the transpeptidation / translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit.</p><p><strong><u>Cardiac electrophysiology: </u></strong></p><p>QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1000 mg) alone or in combination with azithromycin (500 mg, 1000 mg, and 1500 mg once daily). Co-administration of azithromycin increased the QTc interval in a dose- and concentration-dependent manner. In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 (10) ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1000 mg and 1500 mg azithromycin, respectively.</p><p><strong><u>Mechanism of resistance: </u></strong></p><p>The two most frequently encountered mechanisms of resistance to macrolides, including azithromycin, are target modification (most often by methylation of 23S rRNA) and active efflux. The occurrence of these resistance mechanisms varies from species to species and, within a species, the frequency of resistance varies by geographical location.</p><p>The most important ribosomal modification that determines reduced binding of macrolides is post-transcriptional (N6) -dimethylation of adenine at nucleotide A2058</p><p>(<em>Escherichia. coli </em>numbering system) of the 23S rRNA by methylases encoded by <em>erm </em>(<em>e</em>rythromycin <em>r</em>ibosome <em>m</em>ethylase) genes. Ribosomal modifications often determine cross resistance (MLSB phenotype) to other classes of antibiotics whose ribosomal binding sites overlap those of the macrolides: the lincosamides (including clindamycin), and the streptogramin B (which include, for example, the quinupristin component of quinupristin/dalfopristin). Different <em>erm </em>genes are present in different bacterial species, in particular streptococci and staphylococci. Susceptibility to macrolides can also be affected by less frequently encountered mutational changes in nucleotides A2058 and</p><p>A2059, and at some other positions of 23S rRNA, or in the large subunit ribosomal proteins L4 and L22.</p><p>Efflux pumps occur in a number of species, including Gram-negatives, such as <em>Haemophilus influenzae </em>(where they may determine intrinsically higher minimal inhibitory concentrations [MICs]) and staphylococci. In streptococci and enterococci, an efflux pump that recognizes 14- and 15-membered macrolides (which include, respectively, erythromycin and azithromycin) is encoded by <em>mef </em>(A) genes.</p><p><strong><u>Methodology for determining the in vitro susceptibility of bacteria to azithromycin </u></strong></p><p>Susceptibility testing should be conducted using standardized laboratory methods, such as those described by the Clinical and Laboratory Standards Institute (CLSI). These include dilution methods (MIC determination) and disk susceptibility methods. Both CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) provide interpretive criteria for these methods.</p><p>Based on a number of studies, it is recommended that the in vitro activity of azithromycin be tested in ambient air, to ensure physiological pH of the growth medium. Elevated CO2 tensions, as often used for streptococci and anaerobes, and occasionally for other species, result in a reduction in the pH of the medium. This has a greater adverse effect on the apparent potency of azithromycin than on that of other macrolides.</p><p>The CLSI susceptibility breakpoints, based on broth microdilution or agar dilution testing, with incubation in ambient air, are given in the table below.</p><p><strong><u>&nbsp;</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>CLSI Dilution Susceptibility Interpretive Criteria </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Broth microdilution MIC (mg/L) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Organism </strong></p></td><td style="vertical-align:top"><p><strong>Susceptible </strong></p></td><td style="vertical-align:top"><p><strong>Intermediate </strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus </em>species</p></td><td style="vertical-align:top"><p>&le; 4</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>- <sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis </em></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis </em></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>- <sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&ge; 8</p></td></tr><tr><td style="vertical-align:top"><p>Streptococci <sup>a </sup></p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&ge; 2</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a Includes <em>Streptococcus pneumoniae</em>, &beta;-hemolytic streptococci and viridans streptococci.</p><p>b The current absence of data on resistant strains precludes defining any category other than susceptible. If strains yield MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.</p><p>Incubation in ambient air.</p><p>CLSI = Clinical and Laboratory Standards Institute; MIC = Minimal inhibitory concentration.</p><p>Source: CLSI, 2012; CLSI, 2010</p></td></tr></tbody></table><p>Susceptibility can also be determined by the disk diffusion method, measuring inhibition zone diameters after incubation in ambient air. Susceptibility disks contain 15 &mu;g of azithromycin. Interpretive criteria for inhibition zones, established by the CLSI on the basis of their correlation with MIC susceptibility categories, are listed in the table below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>CLSI Disk Zone Interpretive Criteria </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Disk inhibition zone diameter (mm) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Organism </strong></p></td><td style="vertical-align:top"><p><strong>Susceptible </strong></p></td><td style="vertical-align:top"><p><strong>Intermediate </strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus </em>species</p></td><td style="vertical-align:top"><p>&ge; 12</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis </em></p></td><td style="vertical-align:top"><p>&ge; 26</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis </em></p></td><td style="vertical-align:top"><p>&ge; 20</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em></p></td><td style="vertical-align:top"><p>&ge; 18</p></td><td style="vertical-align:top"><p>14 - 17</p></td><td style="vertical-align:top"><p>&le; 13</p></td></tr><tr><td style="vertical-align:top"><p>Streptococci <sup>a </sup></p></td><td style="vertical-align:top"><p>&ge; 18</p></td><td style="vertical-align:top"><p>14 - 17</p></td><td style="vertical-align:top"><p>&le; 13</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a Includes <em>Streptococcus pneumoniae</em>, &beta;-hemolytic streptococci and viridans streptococci.</p><p>Incubation in ambient air.</p><p>CLSI = Clinical and Laboratory Standards Institute; mm = Millimeters.</p><p>Source: CLSI, 2012; CLSI, 2010</p></td></tr></tbody></table><p>The validity of both the dilution and disk diffusion test methods should be verified using quality control (QC) strains, as indicated by the CLSI. Acceptable limits when testing azithromycin against these organisms are listed in the table below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Quality Control Ranges for Azithromycin Susceptibility Tests (CLSI) </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Broth microdilution MIC </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Organism </strong></p></td><td style="vertical-align:top"><p><strong>Quality control range (mg/L azithromycin) </strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em>ATCC 49247</p></td><td style="vertical-align:top"><p>1 &ndash; 4</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em>ATCC 29213</p></td><td style="vertical-align:top"><p>0.5 &ndash; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae&nbsp; </em>ATCC 49619</p></td><td style="vertical-align:top"><p>0.06 &ndash; 0.25</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Disk inhibition zone diameter (15 </strong>&mu;<strong>g disk) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Organism </strong></p></td><td style="vertical-align:top"><p><strong>Quality control range (mm) </strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em>ATCC 49247</p></td><td style="vertical-align:top"><p>13 - 21</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em>ATCC 25923</p></td><td style="vertical-align:top"><p>21 - 26</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae </em>ATCC 49619</p></td><td style="vertical-align:top"><p>19 &ndash; 25</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CLSI = Clinical and Laboratory Standards Institute; MIC = Minimal inhibitory concentration; mm = Millimeters.</p><p>Source: CLSI, 2012.</p></td></tr></tbody></table><p>The EUCAST has also established susceptibility breakpoints for azithromycin based on MIC determination. The EUCAST susceptibility criteria are listed in the table below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:530px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>EUCAST Susceptibility Breakpoints for Azithromycin </strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Organism</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MIC (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Susceptible </strong></p></td><td style="vertical-align:top"><p><strong>Resistant </strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>species</p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae </em></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&gt; 0.5</p></td></tr><tr><td style="vertical-align:top"><p>&beta;-hemolytic streptococci <sup>a </sup></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&gt; 0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em></p></td><td style="vertical-align:top"><p>&le; 0.12</p></td><td style="vertical-align:top"><p>&gt; 4</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis </em></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&gt; 0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae </em></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&gt; 0.5</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Includes Groups A, B, C, G. EUCAST = European Committee on Antimicrobial Susceptibility Testing; MIC = Minimal inhibitory concentration</p></td></tr></tbody></table><p><strong>Antibacterial Spectrum </strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>Azithromycin demonstrates cross resistance with erythromycin-resistant Gram-positive isolates. As discussed above, some ribosomal modifications determine cross resistance with other classes of antibiotics whose ribosomal binding sites overlap those of the macrolides: the lincosamides (including clindamycin), and the streptogramins B (which include, for example, the quinupristin component of quinupristin/dalfopristin). A decrease in macrolide susceptibility over time has been noted in particular in <em>Streptococcus pneumoniae </em>and <em>Staphylococcus aureus</em>, and has also been observed in viridans streptococci and <em>Streptococcus agalactiae. </em></p><p>Organisms that are commonly susceptible to azithromycin include:</p><p>Aerobic and facultative Gram-positive bacteria (erythromycin-susceptible isolates): <em>S aureus</em>, <em>Streptococcus agalactiae</em>,* <em>S pneumoniae</em>*, <em>Streptococcus pyogenes</em>*, other &beta;-hemolytic streptococci (Groups C, F, G), and viridans streptococci. Macrolide-resistant isolates are encountered relatively frequently among aerobic and facultative Gram-positive bacteria, in particular among methicillin-resistant <em>S. aureus </em>(MRSA) and penicillin-resistant <em>S. pneumoniae </em>(PRSP).</p><p>Aerobic and facultative Gram-negative bacteria: <em>Bordetella pertussis</em>, <em>Campylobacter jejuni</em>, <em>Haemophilus ducreyi</em>*, <em>Haemophilus influenzae</em>*, <em>Haemophilus parainfluenzae</em>*, <em>Legionella pneumophila</em>, <em>Moraxella catarrhalis</em>*, and <em>Neisseria gonorrhoeae</em>*. <em>Pseudomonas </em>spp. and most <em>Enterobacteriaceae </em>are inherently resistant to azithromycin, although azithromycin has been used to treat <em>Salmonella enterica </em>infections.</p><p>Anaerobes: <em>Clostridium perfringens</em>, <em>Peptostreptococcus </em>spp. and <em>Prevotella bivia</em>.</p><p>Other bacterial species: <em>Borrelia burgdorferi</em>, <em>Chlamydia trachomatis</em>, <em>Chlamydophila pneumoniae</em>*, <em>Mycoplasma pneumoniae</em>*, <em>Treponema pallidum</em>, and <em>Ureaplasma urealyticum</em>.</p><p>Opportunistic pathogens associated with HIV infection: MAC* and the eukaryotic microorganisms <em>Pneumocystis jirovecii </em>and <em>Toxoplasma gondii</em>.</p><p>* The efficacy of azithromycin against the indicated species has been demonstrated in clinical trials.</p><p><strong><u>Paediatric population </u></strong></p><p>Following the assessment of studies conducted in children, the use of azithromycin is not recommended for the treatment of malaria, neither as monotherapy nor combined with chloroquine or artemisinin based drugs, as non-inferiority to anti-malarial drugs recommended in the treatment of uncomplicated malaria was not established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Bioavailability after oral administration is approximately 37%. Peak plasma concentrations are attained 2-3 hours after taking the medicinal product.</p><p><strong><u>Distribution</u></strong></p><p>Orally administered azithromycin is widely distributed throughout the body. In pharmacokinetic studies it has been demonstrated that the concentrations of azithromycin measured in tissues are noticeably higher (as much as 50 times) than those measured in plasma, which indicates that the agent strongly binds to tissues.</p><p>Binding to serum proteins varies according to plasma concentration and ranges from 12% at 0.5 microgram/ml up to 52% at 0.05 microgram azithromycin/ml serum. The mean volume of distribution at steady state (VVss) has been calculated to be 31.1 l/kg.</p><p><strong><u>Elimination</u></strong></p><p>The terminal plasma elimination half-life closely reflects the elimination half-life from tissues of 2-4 days.</p><p>Approximately 12% of an intravenously administered dose of azithromycin is excreted unchanged in urine within the following three days. Particularly high concentrations of unchanged azithromycin have been found in human bile. Also in bile, ten metabolites were detected, which were formed through N- and O- demethylation, hydroxylation of desosamine &ndash; and aglycone rings and cleavage of cladinose conjugate. Comparison of the results of liquid chromatography and microbiological analyses has shown that the metabolites of azithromycin are not microbiologically active.</p><p>In animal tests, high concentrations of azithromycin have been found in phagocytes. It has also been established that during active phagocytosis higher concentrations of azithromycin are released from inactive phagocytes. In animal models this results in high concentrations of azithromycin being delivered to the site of infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Phospholipidosis (intracellular phospholipid accumulation) has been observed in several tissues (e.g. eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) of mice, rats, and dogs given multiple doses of azithromycin. Phospholipidosis has been observed to a similar extent in the tissues of neonatal rats and dogs. The effect has been&nbsp;shown to be reversible after cessation of azithromycin treatment. The significance of the finding for animals and for humans is unknown.</p><p><strong><u>Carcinogenic potential:</u></strong></p><p>Long-term studies in animals have not been performed to evaluate carcinogenic potential as the drug is indicated for short-term treatment only and there were no signs indicative of carcinogenic activity.</p><p><strong><u>Mutagenic potential:</u></strong></p><p>There was no evidence of a potential for genetic and chromosome mutations in in-vivo and in-vitro test models.</p><p><strong><u>Reproductive toxicity:</u></strong></p><p>In animal studies for embryotoxic effects of the substance, no teratogenic effect was observed in mice and rats. In rats, azithromycin doses of 100 and 200 mg/kg bodyweight/day led to mild retardation of fetal ossification and in maternal weight gain. In peri- and postnatal studies in rats, mild retardation following treatment with 50mg/kg/day azithromycin and above was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:522px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium phosphate tribasic</p></td></tr><tr><td style="vertical-align:top"><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium benzoate</p></td></tr><tr><td style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydroxyl propyl cellulose</p></td></tr><tr><td style="vertical-align:top"><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Xanthan gum</p></td></tr><tr><td style="vertical-align:top"><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cherry flavour permaseal</p></td></tr><tr><td style="vertical-align:top"><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vanilla dry flavour</p></td></tr><tr><td style="vertical-align:top"><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Banana dry flavour</p></td></tr><tr><td style="vertical-align:top"><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Castor sugar **</p></td></tr></tbody></table><p>&nbsp;</p><p>** Quantity of Castor Sugar may vary to adjust the quantity (desired potency) of Azithromycin and Sodium benzoate.</p><table border="0" cellspacing="0" cellpadding="0" style="width:653px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before reconstitution, store below 30&ordm;C, in a dry place</p><p>After reconstitution, store in a refrigerator and use within 7 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pack of 15mL:</strong> pack of 15mL (when reconstituted) in a sealed, labelled amber coloured glass bottle with mark and an ampoule of 7mL water for reconstitution, in a printed carton along with a leaflet and provided with CRC cap and measuring device.</p><p><strong>Pack of 30mL:</strong> pack of 30mL (when reconstituted) in a sealed, labelled amber coloured glass bottle with mark and an ampoule of 14mL water for reconstitution, in a printed carton along with a leaflet and provided with CRC cap and measuring device.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street,
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20. July. 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>